Chimeric Antigen Receptor T Cell Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chimeric Antigen Receptor T Cell stocks.

Chimeric Antigen Receptor T Cell Stocks Recent News

Date Stock Title
May 6 CARM Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
May 3 NTLA Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
May 3 NTLA IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 3 TSVT 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
May 3 PSTX Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
May 2 JANX Janux Therapeutics gains amid renewed takeover speculation
May 2 CARM Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
May 2 CARM Carisma Therapeutics names Eugene Kennedy as chief medical officer
May 2 CARM Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
May 2 NTLA Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
May 2 PSTX Xyphos and Poseida to develop allogeneic cell therapies for cancer
May 1 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
May 1 PSTX Poseida gains on cell therapy pact with Astellas
May 1 PSTX Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
May 1 PSTX Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
Apr 30 ACET Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Apr 30 JANX Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
Apr 30 SNTI Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
Chimeric Antigen Receptor T Cell

Chimeric Antigen Receptor T Cell (CAR-T) is a type of immunotherapy that uses a patient’s own T cells to fight cancer. The T cells are genetically modified to express a special receptor, called a chimeric antigen receptor (CAR), which is designed to recognize and bind to a specific protein found on the surface of cancer cells. Once the CAR-T cells bind to the cancer cells, they can kill them. CAR-T therapy has been used to treat certain types of blood cancers, such as leukemia and lymphoma, and is being studied for other types of cancer.

Browse All Tags